entertainment -WSS

entertainment

author：focus 2025-10-02 20:06:31 - browse：6

research funding, medical devices — APStock

WASHINGTON — A federal district judge on Monday granted the Biden administration’s request to dismiss a lawsuit challenging Medicare’s new drug price negotiation program from the drug industry lobbying organization PhRMA.

The move is an early but positive sign for the Biden administration in a legal fight that could stretch for years, as a host of major drugmakers, including Merck, Bristol Myers Squibb, and Johnson & Johnson, have also filed lawsuits over the constitutionality of Medicare’s new powers. The first round of drug negotiations is ongoing, and a judge heard oral arguments in a challenge brought by AstraZeneca just last month.

Newsletters

Sign up for D.C. Diagnosis

Washington never stops. Cut through the noise with our essential updates on health care politics and policy

Please enter a valid email address. Privacy Policy

The National Infusion Center Association and the Global Colon Cancer Association are also plaintiffs in PhRMA’s lawsuit. The judge dismissed the National Infusion Center Association from the case because it did not have subject matter jurisdiction to bring the lawsuit. And because NICA was the only party to the lawsuit that resides in Texas, the judge tossed out the case in its entirety.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： Democrats decry new health bill for going easy on private equity

WSS

What is the Wagner Group? The 'brutal' Russian military unit in Ukraine

CDC Director Mandy Cohen on transparency, trust, and health

Cloning humans is technically possible. It's curious no one has tried

What it's like to live with paralysis for one psychologist

STAT Report: Patient voices and perspectives

Disclosing genetic information: not as worrisome as once feared

leisure time

entertainment

Sign up for D.C. Diagnosis

Wikipedia

BioMarin wins approval for gene therapy to treat hemophilia A

UHS says company favors patients whose insurance pays more

As demand for Covid shots wanes, Moderna seeks its next success

Paxlovid study fails to answer questions over benefit for broader groups

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Former reverend arrested for allegedly killing 8

Walensky prepares to leave CDC — and Congress — behind

Donald Trump's relentless attacks on special counsel Jack Smith

Hepatitis C has a cure — but many Americans still lack access to it

Senate panel puts off hardest PBM reforms for another day

hotspot

New Alzheimer's drugs heat up race for early detection blood tests

Cloning humans is technically possible. It's curious no one has tried

Bronny James, LeBron's son, suffers cardiac arrest during basketball practice at USC

Truvian presents data for its desktop blood

#NeedHerScience: shining a light on gender disparities in medicine

UHS says company favors patients whose insurance pays more

leisure time

knowledge

knowledge

leisure time